ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

iSpecimen Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.91−0.01 (-0.75%)

Close on Oct 19, 2026

Market cap: $1.27M
P/E (TTM): –
Dividend yield: –

Dividends

iSpecimen has not reported a dividend

No dividend per share appears in iSpecimen's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in iSpecimen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-40 reverse split on May 18, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ISPC.

Revenue growth-92.1% · median -37.7%

Gross margin-98.0% · median 78.8%

Operating margin-2020.0% · median -509.2%

Net margin-2449.0% · median -500.5%

Company	Revenue	Growth
MXCT	$31.05M	-13.2%
ABSI	$1.56M	-62.3%
ONMD	$1.46M	+216.5%
ISPC	$466.30K	-92.1%
CBIH	$123.63K	-64.1%
VSBC	$0	–

Company

Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 53
Held by institutions: 2.3%
Auditor: Bush & Associates CPA LLC
SEC CIK: 1558569

Advertisement
300 × 250